导航菜单
From October 20 to 28, a total of seven new cosmetic ingredients completed notification with China's National Medical Products Administration (NMPA). The technical requirements for all related NCIs have not yet been publicly disclosed.
This cyclic peptide marks the seventh peptide-based new cosmetic ingredient filed by Zhejiang Peptides. ZMUni Compliance Centre is pleased to have supported our long-term partner in completing the filing of another innovative peptide ingredient in China.
For the first time, a university has filed an NCI in China as the applicant. The applicant, Southern Medical University, was founded in 1951 as the First Military Medical University of the Chinese People's Liberation Army and transferred to the Guangdong Provincial Government in August 2004, when it was renamed Southern Medical University. The university is engaged in higher education and scientific research.
Lacto-N-neotetraose (LNnT) is a human milk oligosaccharide (HMO) composed of galactose, glucose, and N-acetylglucosamine. It offers potential benefits for skin hydration, skin protection, and hair conditioning. This marks the third NCI notification for LNnT in China, with the notifier being a subsidiary of Bloomage Biotech.
Badger oil is a refined oil obtained by rendering the subcutaneous fat of the Asian badger (Meles leucurus). It is typically pale yellow with a smooth, emollient texture. Traditionally used topically for minor burns, chilblains, and dry, cracked skin, it may help form a protective film on the skin surface and support skin moisturization and conditioning.
Rhamnose Acetamide marks the first new cosmetic ingredient (NCI) notification in China by LG H&H Co., Ltd., part of South Korea's LG Group.
In September 2026, LG H&H also published an international patent application, WO2026187034A1, titled Monosaccharide Derivative and Use Thereof. The application describes potential cosmetic applications involving skin hydration, barrier function, elasticity, and wrinkle reduction. However, it is unclear whether the compounds described in the patent are related to the newly filed Rhamnose Acetamide.
Trollius chinensis is a plant in the Ranunculaceae family, also known as Chinese globeflower. Traditionally used in Chinese medicine, it is valued for its heat-clearing, detoxifying, antibacterial, and anti-inflammatory properties and has been used for conditions such as upper respiratory tract infections, tonsillitis, and pharyngitis.
